Blog
RSS FeedPosted by Michael Wonder on 22 Jun 2023
PHARMAC considers widening access to treatments for multiple sclerosis and haemophilia A
22 June 2023 - PHARMAC has started a consultation today for widening access for two treatments; ocrelizumab (Ocrevus) as the first ...
Posted by Michael Wonder on 23 Mar 2023
PHARMAC considers funding rituximab for IgG4 related disease
23 March 2023 - PHARMAC has initiated a consultation today on widening funded access to rituximab (branded as Riximyo) for ...
Posted by Michael Wonder on 19 Sep 2022
PHARMAC considering multiple new treatments from Takeda
19 September 2022 - Pharmac has initiated consultation today on a provisional bundle deal with Takeda to fund vedolizumab for people ...
Posted by Michael Wonder on 15 Sep 2022
Can the proposed listing of two medicines from the same supplier really be called a bundle deal?
16 September 2022 - On Wednesday, PHARMAC announced a "medicines bundle to provide more treatment options for New Zealanders." ...
Posted by Michael Wonder on 14 Sep 2022
PHARMAC announces medicines bundle to provide more treatment options for New Zealanders
14 September 2022 - PHARMAC is considering funding two medicines as part of a new bundle agreement that would offer ...
Posted by Michael Wonder on 06 Jul 2022
PHARMAC opens door to funding Keytruda in 'biggest step forward in treatment of lung cancer'
6 July 2022 - Keytruda has been called a 'miracle' drug, and there's a glimmer of hope now for those ...
Posted by Michael Wonder on 06 Jul 2022
PHARMAC considering funding new medicines for lung cancer
6 July 2022 - PHARMAC is seeking proposals from pharmaceutical suppliers for medicines that could treat New Zealanders with lung ...
Posted by Michael Wonder on 14 Feb 2022
PHARMAC proposing to widen access to funded medicines
14 February 2022 - PHARMAC has issued a consultation today on proposals to widen access to two medicines, rituximab and zoledronic ...
Posted by Michael Wonder on 26 Aug 2021
PHARMAC seeks feedback on a biosimilar brand of adalimumab being considered for funding
26 August 2021 - PHARMAC is considering awarding Principal Supply to a biosimilar brand of adalimumab (Amgevita) from 1 February ...
Posted by Michael Wonder on 22 Jun 2021
Proposal for the supply of primidone and gabapentin
22 June 2021 - PHARMAC is seeking additional feedback on a proposal to change the funded brands of primidone tablets ...
Posted by Michael Wonder on 01 Mar 2021
Proposal to fully fund Mercilon 28 for oral contraception
26 February 2021 - PHARMAC is seeking feedback on a proposal to increase the subsidy to fully fund ethinyloestradiol 20 ...
Posted by Michael Wonder on 04 Dec 2020
Proposal to widen access to rituximab for treatment of membranous nephropathy
4 December 2020 - PHARMAC is seeking feedback on a proposal to widen access to rituximab. ...
Posted by Michael Wonder on 12 Nov 2020
Proposal to widen access to valganciclovir for transplant patients
12 November 2020 - PHARMAC is seeking feedback on a proposal to widen access to valganciclovir. ...
Posted by Michael Wonder on 02 Oct 2020
Proposal to widen access to sirolimus for lymphovascular malformations and tuberous sclerosis complex complications
2 October 2020 - PHARMAC is seeking feedback on a proposal to widen funded access to sirolimus from 1 February ...
Posted by Michael Wonder on 18 Sep 2020
Proposal to fund emicizumab for people with haemophilia A
18 September 2020 - PHARMAC is seeking feedback on a proposal to fund emicizumab (Hemlibra), a new treatment for people with ...